Biotechnology company dedicated to the development of new medication and biomarkers in the field of organ transplants and immunology in general.
The project was part of an academic environment and at the moment is being set up as a company which is expected to have its own website, logo and social network presence before August. Recruitment of scientific staff will start in June this year. Once a collaboration agreement with the FIBHPH has been signed, the start of a clinical trial on biomarkers with the Puerta de Hierro Hospital is planned, and work will be continued on Advanced Therapies begun in collaboration with the Department of Cytology at the Rey Juan Carlos University. The first round of capital increase is also scheduled for the same year and government grants will be requested to help recruit specialised staff.
